利用胚系变异估算胶质瘤及其亚型风险
研究采用病例对照设计,基于25个单核苷酸多态性(SNP)联合诊断年龄和性别构建模型,在Mayo Clinic的1273例胶质瘤病例和443例对照中发现,风险评分最高5%的患者发生IDH突变型胶质瘤的相对风险增加超过14倍;预测IDH突变状态的SNP模型验证一致性指数为0.85。作者认为胚系基因分型可为新发现脑病变的初始管理提供新工具,但风险评分不适用于人群筛查,可能对特定临床定义的高危群体有用。
要点
- 风险评分最高5%的患者发生IDH突变型胶质瘤的相对风险增加超过14倍。
- IDH突变型1p/19q非共缺失胶质瘤的终生风险从几乎为零升至2.3%。
- 预测IDH突变状态的SNP模型验证一致性指数为0.85。
核心结论
- 胚系基因分型可为新发现脑病变的初始管理提供新工具。
- 鉴于胶质瘤终生风险低,风险评分不适用于人群筛查;但可能对特定临床定义的高危群体有用。
研究设计与样本
- 采用病例对照设计,使用多项逻辑回归构建模型以估算胶质瘤发生风险并考虑组织学和分子亚型。
- 采用病例-病例设计,使用逻辑回归构建模型以预测异柠檬酸脱氢酶(IDH)突变状态。
- 发现集来自Mayo Clinic的1273例胶质瘤病例和443例对照;验证集来自UCSF的852例胶质瘤病例和231例对照。
- 所有样本使用定制Illumina OncoArray进行基因分型。
主要发现
- 风险评分最高5%的患者发生IDH突变型胶质瘤的相对风险增加超过14倍。
- 在风险评分百分位极端处观察到终生绝对风险的大幅差异。
- IDH突变型1p/19q非共缺失胶质瘤的终生风险从几乎为零升至2.3%。
- IDH突变型1p/19q共缺失胶质瘤的终生风险从几乎为零升至1.7%。
- 预测IDH突变状态的SNP模型验证一致性指数为0.85。
关键数值与推荐
- 风险评分最高5%的患者发生IDH突变型胶质瘤的相对风险增加超过14倍。
- IDH突变型1p/19q非共缺失胶质瘤的终生风险从几乎为零升至2.3%。
- IDH突变型1p/19q共缺失胶质瘤的终生风险从几乎为零升至1.7%。
- 预测IDH突变状态的SNP模型验证一致性指数为0.85。
临床怎么用
- 鉴于胶质瘤终生风险低,风险评分不适用于人群筛查;但可能对特定临床定义的高危群体有用。
- 作者认为胚系基因分型可为新发现脑病变的初始管理提供新工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Twenty-five single nucleotide polymorphisms (SNPs) are associated with adult diffuse glioma risk. We hypothesized that the inclusion of these 25 SNPs with age at diagnosis and sex could estimate risk of glioma as well as identify glioma subtypes. METHODS: Case-control design and multinomial logistic regression were used to develop models to estimate the risk of glioma development while accounting for histologic and molecular subtypes. Case-case design and logistic regression were used to develop models to predict isocitrate dehydrogenase (IDH) mutation status. A total of 1273 glioma cases and 443 controls from Mayo Clinic were used in the discovery set, and 852 glioma cases and 231 controls from UCSF were used in the validation set. All samples were genotyped using a custom Illumina OncoArray. RESULTS: Patients in the highest 5% of the risk score had more than a 14-fold increase in relative risk of developing an IDH mutant glioma. Large differences in lifetime absolute risk were observed at the extremes of the risk score percentile. For both IDH mutant 1p/19q non-codeleted glioma and IDH mutant 1p/19q codeleted glioma, the lifetime risk increased from almost null to 2.3% and almost null to 1.7%, respectively. The SNP-based model that predicted IDH mutation status had a validation concordance index of 0.85. CONCLUSIONS: These results suggest that germline genotyping can provide new tools for the initial management of newly discovered brain lesions. Given the low lifetime risk of glioma, risk scores will not be useful for population screening; however, they may be useful in certain clinically defined high-risk groups.
引用
- Eckel-Passow JE, Decker PA, Kosel ML, et al. Using germline variants to estimate glioma and subtype risks. Neuro Oncol. 2019. PMID: 30624711. doi:10.1093/neuonc/noz009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。